<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="229">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684424</url>
  </required_header>
  <id_info>
    <org_study_id>A0081213</org_study_id>
    <nct_id>NCT00684424</nct_id>
  </id_info>
  <brief_title>Non-Interventional Study With LYRICA (Pregabalin) In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency</brief_title>
  <official_title>Non-Interventional Study (NIS) With Lyrica In Patients With Epilepsy As Adjunctive Therapy Of Partial Seizures To Reduce Seizure Frequency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary efficacy parameter will be the responder rate, defined as the proportion of
      subjects who had at least a 50% reduction in 28 day seizure rate during the maintenance
      phase
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Responders: Number of Subjects With a 50% or Greater Reduction in Seizure Frequency</measure>
    <time_frame>Baseline through Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Responders: number of subjects with a 50 percent (%) or greater reduction in partial seizure frequency from Baseline to Final visit. Seizure frequency in treatment period = total number of partial seizures in maintenance treatment phase * 28 divided by total number of days in the maintenance treatment phase. Missing category includes subjects with missing attack date, insufficient length of treatment period or no seizures in both baseline and treatment periods. Subjects with zero seizures in the baseline period and some seizures in the treatment period were treated as non-responders.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antiepileptic Drugs Used in the Past</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antiepileptic drug history: number of subjects who took each class of antiepileptic drug prior to entering the study. Subjects who took more than one antiepileptic drug were counted for each of the drug classes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 28 Day Partial Seizure Frequency</measure>
    <time_frame>Baseline through Week 16 (Final Visit )</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in 28-day partial seizure frequency between the baseline period and treatment period. Baseline period = the 4 weeks (28 days) prior to Baseline visit. Treatment period = last 12 weeks (84 days) of the study (maintenance treatment phase excluding 4-week titration phase). Seizure frequency in baseline period = total number of partial seizures in baseline phase * 28 divided by total number of days in the baseline phase. Seizure frequency in treatment period = total number of partial seizures in maintenance treatment phase * 28 divided by total number of days in maintenance treatment phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure Freedom: Number of Seizure-free Subjects During the Last 4 Weeks of the Study</measure>
    <time_frame>Week 8 up to Week 16 (Last 4 weeks of the treatment period)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seizure Freedom (responders): subjects with no seizures (partial or other) during the last 4 weeks of the study. Non-responders: subjects with seizures (partial or other)during the last 4 weeks of the study. Subjects, who discontinued less than 4 weeks into the observation period were excluded from analysis. The 4 week period excludes the titration phase of the study. Missing category includes subjects with missing attack date or insufficient length of treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant Drug Treatments</measure>
    <time_frame>Baseline through Week 16 (Final Visit)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Concomitant drugs treatments (drugs other than, and in addition to study medication): number of subjects who took each concomitant drug during the study (baseline through end of study). World Health Organization (WHO) Drug (v02Q2) coding dictionary applied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Dosage of Pregabalin Taken at Baseline and Final Visit</measure>
    <time_frame>Baseline, Week 16 (Final Visit )</time_frame>
    <safety_issue>No</safety_issue>
    <description>Average doses of pregabalin in milligrams per day (mg/day) taken at baseline and final visit shown by number of participants at each dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale of Anxiety (VAS-A)</measure>
    <time_frame>Baseline, Week 4, Week 16 (Final Visit), Last Observation Carried Forward</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual Analog Scale of anxiety self assessment: metric measurement (in 2 mm interval) from the visual analog scale; 0 mm = no anxiety, 100 mm = extreme anxiety at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Final Visit in Visual Analog Scale of Anxiety (VAS-A)</measure>
    <time_frame>Baseline, Week 16 (Final Visit), Last Observation Carried Forward</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visual Analog Scale of anxiety self assessment: metric measurement (in 2 mm interval) from the visual analog scale; 0 mm = no anxiety, 100 mm = extreme anxiety. Change from Baseline to Final Visit: score at final visit minus score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Categorical Scores on Clinical Global Impression of Severity (CGI-S)</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>CGI-S scale: physician's global impression of a subject's clinical condition, at baseline in terms of severity. Numerical scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill subjects). Numbers of subjects in each category are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Categorical Scores on Clinical Global Impression of Change(CGI-C)</measure>
    <time_frame>Week 16 (Final Visit)</time_frame>
    <safety_issue>No</safety_issue>
    <description>CGI-C scale: physician's global impression of a subject's clinical condition in terms of change from baseline. Improvement = CGI response of very much improved, much improved, or minimally improved. No Change = CGI response of no change. Worsening = CGI response of very much worse, much worse or minimally worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Outcomes Sleep Scale (MOS-S)</measure>
    <time_frame>Baseline, Week 16 (Final Visit )</time_frame>
    <safety_issue>No</safety_issue>
    <description>MOS-S: subject reported measure with 12 items that assess key constructs of sleep over the past week. Scoring based on 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes:1, no:0). Six(6) and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range * 100); total score range: 0 to 100; higher score = greater intensity of attribute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Change in Response Categories in Medical Outcomes Sleep Scale (MOS-S): Optimal Sleep Subscale</measure>
    <time_frame>Baseline, Week 16 (Final Visit)</time_frame>
    <safety_issue>No</safety_issue>
    <description>MOS: subject rated questionnaire to assess sleep quality and quantity. Optimal sleep subscale is derived from Sleep Quantity average hours of sleep each night during the past week. Number of subjects with response: YES (Optimal) if sleep quantity was 7 or 8 hours per night, or response = NO (Non-Optimal) if sleep quantity was less than (&lt;) 7 hours per night. Number of participants with shift in response categories from Baseline to Final Visit.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">199</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Outpatients with epilepsy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-Interventional Study</intervention_name>
    <description>Observational Only</description>
    <arm_group_label>Outpatients with epilepsy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        outpatients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age over 18 years old, patients with epilepsia with partial seizures

          -  Enrollment to study is fully on physician decision in compliance with current SPC.

        Exclusion Criteria:

          -  Patient who did not meet indication according to SPC Lyrica
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081213&amp;StudyName=Non-Interventional%20Study%20with%20LYRICA%AE%20In%20Patients%20With%20Epilepsy%20As%20Adjunctive%20Therapy%20Of%20Partial%20Seizures%20To%20Reduce%20Seizure%20Frequency%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2010</verification_date>
  <lastchanged_date>May 27, 2010</lastchanged_date>
  <firstreceived_date>May 22, 2008</firstreceived_date>
  <firstreceived_results_date>March 9, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 36 medical centers and participated in the study between 11 July 2008 and 30 March 2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pregabalin (Lyrica)</title>
          <description>Individualized dose ranging from 150 mg to 600 mg daily administered as two single doses.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="194"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pregabalin (Lyrica)</title>
          <description>Individualized dose ranging from 150 mg to 600 mg daily administered as two single doses.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="199"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>18 - 44 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="104"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>45 - 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;= 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="107"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="92"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Responders: Number of Subjects With a 50% or Greater Reduction in Seizure Frequency</title>
        <description>Responders: number of subjects with a 50 percent (%) or greater reduction in partial seizure frequency from Baseline to Final visit. Seizure frequency in treatment period = total number of partial seizures in maintenance treatment phase * 28 divided by total number of days in the maintenance treatment phase. Missing category includes subjects with missing attack date, insufficient length of treatment period or no seizures in both baseline and treatment periods. Subjects with zero seizures in the baseline period and some seizures in the treatment period were treated as non-responders.</description>
        <time_frame>Baseline through Week 16</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set: all subjects who received at least 1 dose of study drug and had at least 1 efficacy measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin (Lyrica)</title>
            <description>Individualized dose ranging from 150 mg to 600 mg daily administered as two single doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="199"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Responders: Number of Subjects With a 50% or Greater Reduction in Seizure Frequency</title>
            <description>Responders: number of subjects with a 50 percent (%) or greater reduction in partial seizure frequency from Baseline to Final visit. Seizure frequency in treatment period = total number of partial seizures in maintenance treatment phase * 28 divided by total number of days in the maintenance treatment phase. Missing category includes subjects with missing attack date, insufficient length of treatment period or no seizures in both baseline and treatment periods. Subjects with zero seizures in the baseline period and some seizures in the treatment period were treated as non-responders.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Responders</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="138"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-Responders</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Missing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antiepileptic Drugs Used in the Past</title>
        <description>Antiepileptic drug history: number of subjects who took each class of antiepileptic drug prior to entering the study. Subjects who took more than one antiepileptic drug were counted for each of the drug classes.</description>
        <time_frame>Baseline</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety analysis set: all subjects who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin (Lyrica)</title>
            <description>Individualized dose ranging from 150 mg to 600 mg daily administered as two single doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="199"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Antiepileptic Drugs Used in the Past</title>
            <description>Antiepileptic drug history: number of subjects who took each class of antiepileptic drug prior to entering the study. Subjects who took more than one antiepileptic drug were counted for each of the drug classes.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Barbiturates</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Carbamazepine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gabapentin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lamotrigine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="38"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Levetiracetam</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Phenytoin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Tiagabine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Topiramate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Valproate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="97"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vigabatrine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Other</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Missing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No previous treatment</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 28 Day Partial Seizure Frequency</title>
        <description>Change in 28-day partial seizure frequency between the baseline period and treatment period. Baseline period = the 4 weeks (28 days) prior to Baseline visit. Treatment period = last 12 weeks (84 days) of the study (maintenance treatment phase excluding 4-week titration phase). Seizure frequency in baseline period = total number of partial seizures in baseline phase * 28 divided by total number of days in the baseline phase. Seizure frequency in treatment period = total number of partial seizures in maintenance treatment phase * 28 divided by total number of days in maintenance treatment phase.</description>
        <time_frame>Baseline through Week 16 (Final Visit )</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS. Subjects who discontinued less than 4 weeks into the treatment period or with missing date of the attack were excluded from analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="196"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in 28 Day Partial Seizure Frequency</title>
            <description>Change in 28-day partial seizure frequency between the baseline period and treatment period. Baseline period = the 4 weeks (28 days) prior to Baseline visit. Treatment period = last 12 weeks (84 days) of the study (maintenance treatment phase excluding 4-week titration phase). Seizure frequency in baseline period = total number of partial seizures in baseline phase * 28 divided by total number of days in the baseline phase. Seizure frequency in treatment period = total number of partial seizures in maintenance treatment phase * 28 divided by total number of days in maintenance treatment phase.</description>
            <units>number of seizures per 28 days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline Period</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.20" spread="3.375"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Treatment Period</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.339" spread="2.5177"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline to Treatment Period</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.860" spread="2.0494"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>R-ratio of seizure frequency summaries = [(t-b)/(t+b)]*100; where t= treatment seizure frequency and b= baseline seizure frequency.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>R-ratio</param_type>
            <param_value>-56.723</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>46.9499</dispersion_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seizure Freedom: Number of Seizure-free Subjects During the Last 4 Weeks of the Study</title>
        <description>Seizure Freedom (responders): subjects with no seizures (partial or other) during the last 4 weeks of the study. Non-responders: subjects with seizures (partial or other)during the last 4 weeks of the study. Subjects, who discontinued less than 4 weeks into the observation period were excluded from analysis. The 4 week period excludes the titration phase of the study. Missing category includes subjects with missing attack date or insufficient length of treatment period.</description>
        <time_frame>Week 8 up to Week 16 (Last 4 weeks of the treatment period)</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin (Lyrica)</title>
            <description>Individualized dose ranging from 150 mg to 600 mg daily administered as two single doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="199"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Seizure Freedom: Number of Seizure-free Subjects During the Last 4 Weeks of the Study</title>
            <description>Seizure Freedom (responders): subjects with no seizures (partial or other) during the last 4 weeks of the study. Non-responders: subjects with seizures (partial or other)during the last 4 weeks of the study. Subjects, who discontinued less than 4 weeks into the observation period were excluded from analysis. The 4 week period excludes the titration phase of the study. Missing category includes subjects with missing attack date or insufficient length of treatment period.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Responders: Seizure-free</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="119"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-responders: With Seizures</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="77"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Missing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concomitant Drug Treatments</title>
        <description>Concomitant drugs treatments (drugs other than, and in addition to study medication): number of subjects who took each concomitant drug during the study (baseline through end of study). World Health Organization (WHO) Drug (v02Q2) coding dictionary applied.</description>
        <time_frame>Baseline through Week 16 (Final Visit)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin (Lyrica)</title>
            <description>Individualized dose ranging from 150 mg to 600 mg daily administered as two single doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="199"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Concomitant Drug Treatments</title>
            <description>Concomitant drugs treatments (drugs other than, and in addition to study medication): number of subjects who took each concomitant drug during the study (baseline through end of study). World Health Organization (WHO) Drug (v02Q2) coding dictionary applied.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Acetylsalicylic acid</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Acidum folicum</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alendronic acid</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Alprazolam</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Amlodipine besilate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Amlozek</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anopyrin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Atorvastatin calcium</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Aurorix</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Biston</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Carbamazepine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cipralex</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Citalopram</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Citalopram hydrobromide</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Clonazepam</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Colecalciferol</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Depakine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Depakine chrono</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Detralex</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarel</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diazepam</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dipyridamole</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Enelbin - slow release</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Euthyrox</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Felodipine/ramipril</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fenytoin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fluanxol depot</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gabapentin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Gabitril</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Geratam</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ginko biloba</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glibenclamide</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Glucobene</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Godasal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hypnogen</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Keppra</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lamictal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lamotrigine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Letrox</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Levetiracetam</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Levothyroxine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lexaurin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lipanthyl</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lispril</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Liskantin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lokren</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lusopress</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Magnesium</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Magnesium lactate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Metformin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Metoprolol</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Micardis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Neurontin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Neurotop</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Neurotop - slow release</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Omeprazol</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Omeprazole</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Paroxetine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pentomer</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Perindopril</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Perindopril erbumine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Phenytoin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Piracetam</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Prestarium</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Primdone</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ramipril</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ramipril/hydrochlorothiazide</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rivotril</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rufinamide</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sabril</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sanepil</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Seretide diskus</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sertraline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Simepar</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Simvastatin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Siofor</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sodanton</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sorbimon</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sumatriptan</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Symbicort turbuhaler &quot;Draco&quot;</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Tegretol</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Tegretol CR</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ticlopidine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Timonil</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Timonil - slow release</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Topamax</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Topiramate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Trandlapril</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Valproate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Valproate sodium</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Valproic acid</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vasocardin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vinpocetine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Warfarin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Zocor</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Zoloft</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Dosage of Pregabalin Taken at Baseline and Final Visit</title>
        <description>Average doses of pregabalin in milligrams per day (mg/day) taken at baseline and final visit shown by number of participants at each dose.</description>
        <time_frame>Baseline, Week 16 (Final Visit )</time_frame>
        <safety_issue>No</safety_issue>
        <population>Safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin (Lyrica)</title>
            <description>Individualized dose ranging from 150 mg to 600 mg daily administered as two single doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="199"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Average Dosage of Pregabalin Taken at Baseline and Final Visit</title>
            <description>Average doses of pregabalin in milligrams per day (mg/day) taken at baseline and final visit shown by number of participants at each dose.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Baseline: 75 mg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline:100 mg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: 130 mg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: 150 mg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="166"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: 225 mg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: 300 mg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: 375 mg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: 450 mg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: 525 mg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: 600 mg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Visit: 75 mg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Visit: 100 mg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Visit: 130 mg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Visit: 150 mg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Visit: 225 mg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Visit: 300 mg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Visit: 375 mg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Visit: 450 mg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Visit: 525 mg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Visit: 600 mg</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale of Anxiety (VAS-A)</title>
        <description>Visual Analog Scale of anxiety self assessment: metric measurement (in 2 mm interval) from the visual analog scale; 0 mm = no anxiety, 100 mm = extreme anxiety at each visit.</description>
        <time_frame>Baseline, Week 4, Week 16 (Final Visit), Last Observation Carried Forward</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; Last observation carried forward (LOCF) method: subjects last available post-baseline observation was used if data were missing. In this case, data from Visit 2 were carried forward if final visit data were missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin (Lyrica)</title>
            <description>Individualized dose ranging from 150 mg to 600 mg daily administered as two single doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="199"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Visual Analog Scale of Anxiety (VAS-A)</title>
            <description>Visual Analog Scale of anxiety self assessment: metric measurement (in 2 mm interval) from the visual analog scale; 0 mm = no anxiety, 100 mm = extreme anxiety at each visit.</description>
            <units>mm</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline (n=197)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47.1" spread="21.52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4 (Visit 2 ) (n=196)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36.7" spread="18.43"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 16 (Final Visit ) (n=197)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.0" spread="17.05"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Last Observation Carried Forward (LOCF) (n=198)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.0" spread="17.03"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Final Visit in Visual Analog Scale of Anxiety (VAS-A)</title>
        <description>Visual Analog Scale of anxiety self assessment: metric measurement (in 2 mm interval) from the visual analog scale; 0 mm = no anxiety, 100 mm = extreme anxiety. Change from Baseline to Final Visit: score at final visit minus score at baseline.</description>
        <time_frame>Baseline, Week 16 (Final Visit), Last Observation Carried Forward</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; Last observation carried forward (LOCF) method: subjects last available post-baseline observation was used if data were missing. In this case, data from Visit 2 were carried forward if final visit data were missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin (Lyrica)</title>
            <description>Individualized dose ranging from 150 mg to 600 mg daily administered as two single doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="199"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline to Final Visit in Visual Analog Scale of Anxiety (VAS-A)</title>
            <description>Visual Analog Scale of anxiety self assessment: metric measurement (in 2 mm interval) from the visual analog scale; 0 mm = no anxiety, 100 mm = extreme anxiety. Change from Baseline to Final Visit: score at final visit minus score at baseline.</description>
            <units>mm</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Change from Baseline to Week 16 (n=196)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-18.2" spread="17.61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline to LOCF (n=197)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-18.1" spread="17.64"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Categorical Scores on Clinical Global Impression of Severity (CGI-S)</title>
        <description>CGI-S scale: physicians global impression of a subjects clinical condition, at baseline in terms of severity. Numerical scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill subjects). Numbers of subjects in each category are presented.</description>
        <time_frame>Baseline</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin (Lyrica)</title>
            <description>Individualized dose ranging from 150 mg to 600 mg daily administered as two single doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="199"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Categorical Scores on Clinical Global Impression of Severity (CGI-S)</title>
            <description>CGI-S scale: physicians global impression of a subjects clinical condition, at baseline in terms of severity. Numerical scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill subjects). Numbers of subjects in each category are presented.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Normal, not at all ill</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Borderline mentally ill</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="77"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mildly ill</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Moderately ill</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Markedly ill</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Severely ill</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Among the most extremely ill patients</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Categorical Scores on Clinical Global Impression of Change(CGI-C)</title>
        <description>CGI-C scale: physicians global impression of a subjects clinical condition in terms of change from baseline. Improvement = CGI response of very much improved, much improved, or minimally improved. No Change = CGI response of no change. Worsening = CGI response of very much worse, much worse or minimally worse.</description>
        <time_frame>Week 16 (Final Visit)</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin (Lyrica)</title>
            <description>Individualized dose ranging from 150 mg to 600 mg daily administered as two single doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="199"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Categorical Scores on Clinical Global Impression of Change(CGI-C)</title>
            <description>CGI-C scale: physicians global impression of a subjects clinical condition in terms of change from baseline. Improvement = CGI response of very much improved, much improved, or minimally improved. No Change = CGI response of no change. Worsening = CGI response of very much worse, much worse or minimally worse.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Improvement</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="174"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No Change</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Worsening</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Missing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medical Outcomes Sleep Scale (MOS-S)</title>
        <description>MOS-S: subject reported measure with 12 items that assess key constructs of sleep over the past week. Scoring based on 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes:1, no:0). Six(6) and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range * 100); total score range: 0 to 100; higher score = greater intensity of attribute.</description>
        <time_frame>Baseline, Week 16 (Final Visit )</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS. A subscale was classified as missing if any of the questions used in the calculation were missing. Abbreviations: BL = Baseline, SOB = short of breath.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin (Lyrica)</title>
            <description>Individualized dose ranging from 150 mg to 600 mg daily administered as two single doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="199"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Medical Outcomes Sleep Scale (MOS-S)</title>
            <description>MOS-S: subject reported measure with 12 items that assess key constructs of sleep over the past week. Scoring based on 7 subscales: sleep disturbance, snoring, awakened short of breath or with headache, sleep adequacy, and somnolence (range:0-100); sleep quantity (range:0-24), and optimal sleep (yes:1, no:0). Six(6) and 9 item index measures of sleep disturbance were constructed to provide composite scores. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range * 100); total score range: 0 to 100; higher score = greater intensity of attribute.</description>
            <units>scores on scales</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline: Sleep Disturbance</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37.86" spread="20.643"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Snoring</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.1" spread="21.31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Awaken Short of Breath or With Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18.5" spread="19.26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Quantity of Sleep</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" spread="1.40"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Sleep Adequacy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47.51" spread="24.336"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Somnolence</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35.99" spread="16.197"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Sleep 6-Item Index</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="38.74" spread="17.522"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline: Sleep 9-Item Index</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="38.82" spread="16.840"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Visit: Sleep Disturbance</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25.21" spread="15.670"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Visit: Snoring</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26.5" spread="21.86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Vst: Awaken Short of Breath or With Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15.1" spread="16.68"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Visit: Quantity of Sleep</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.5" spread="1.31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Visit: Sleep Adequacy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="60.00" spread="22.113"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Visit: Somnolence</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30.09" spread="15.398"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Visit: Sleep 6-Item Index</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.30" spread="14.501"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Final Visit: Sleep 9-Item Index</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28.69" spread="13.399"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from BL: Sleep Disturbance</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-13.07" spread="17.010"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from BL: Snoring</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.9" spread="13.01"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from BL: Awaken SOB or Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.8" spread="13.55"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from BL: Quantity of Sleep</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.6" spread="1.23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from BL: Sleep Adequacy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13.02" spread="19.636"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from BL: Somnolence</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-6.18" spread="14.399"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from BL: Sleep 6-Item Index</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-9.88" spread="13.641"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from BL: Sleep 9-Item Index</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-10.54" spread="13.280"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Change in Response Categories in Medical Outcomes Sleep Scale (MOS-S): Optimal Sleep Subscale</title>
        <description>MOS: subject rated questionnaire to assess sleep quality and quantity. Optimal sleep subscale is derived from Sleep Quantity average hours of sleep each night during the past week. Number of subjects with response: YES (Optimal) if sleep quantity was 7 or 8 hours per night, or response = NO (Non-Optimal) if sleep quantity was less than (&lt;) 7 hours per night. Number of participants with shift in response categories from Baseline to Final Visit.</description>
        <time_frame>Baseline, Week 16 (Final Visit)</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS. Abbreviations: BL = Baseline; FV = Final Visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin (Lyrica)</title>
            <description>Individualized dose ranging from 150 mg to 600 mg daily administered as two single doses.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="199"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Change in Response Categories in Medical Outcomes Sleep Scale (MOS-S): Optimal Sleep Subscale</title>
            <description>MOS: subject rated questionnaire to assess sleep quality and quantity. Optimal sleep subscale is derived from Sleep Quantity average hours of sleep each night during the past week. Number of subjects with response: YES (Optimal) if sleep quantity was 7 or 8 hours per night, or response = NO (Non-Optimal) if sleep quantity was less than (&lt;) 7 hours per night. Number of participants with shift in response categories from Baseline to Final Visit.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>BL: Optimal Sleep; FV: Optimal Sleep</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BL: Optimal Sleep; FV: Non-Optimal Sleep</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BL: Optimal Sleep; FV: Missing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BL: Non-Optimal Sleep; FV: Optimal Sleep</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BL: Non-Optimal Sleep; FV: Non-Optimal Sleep</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BL: Non-Optimal Sleep; FV: Missing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BL: Missing; FV: Optimal Sleep</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BL: Missing; FV: Non-Optimal Sleep</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>BL: Missing; FV: Missing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pregabalin (Lyrica)</title>
          <description>Individualized dose ranging from 150 mg to 600 mg daily administered as two single doses.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (12.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt; 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt; 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
